Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
Clinical trial NCT05650723 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05650723
- Sponsor
- Weill Medical College of Cornell University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-08
- Primary completion
- 2027-03-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.